Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Kailera Therapeutics, Inc.NASDAQ: KLRA
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow of $667.03M in Q2 FY2026
Q2 FY2026 financing cash flow was $667.03M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 598.66M USD
- Year-over-year change
- —
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 598.66M | — |
Financing Cash Flow vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's FY2025 financing cash flow of $598.66M is the largest of the 10 companies compared; the peer median is $108.9M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
KLRAKailera Therapeutics, Inc. | FY2025 | $598.66M | — | — | — |
| LTM Mar 2026 | $251.49M | +466.1% | +53.9% | 698594.4% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $189.81M | +0.4% | +60.3% | — |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $136.68M | -35.4% | +66.2% | 1325.0% |
| LTM Jun 2026 | $111.25M | +2441.0% | +163.8% | — | |
| LTM Mar 2026 | $108.9M | +27468.4% | +189.0% | — | |
| LTM Mar 2026 | $77.44M | +3044.2% | +76.9% | 210.2% | |
| LTM Mar 2026 | $64.53M | +1243.2% | +279.8% | — | |
| LTM Jun 2026 | $41.68M | -91.1% | -57.8% | 585.3% | |
| LTM Mar 2026 | $15.14M | -54.2% | — | — | |
| Peer median (excluding KLRA) | $108.9M | +466.1% | +71.6% | 955.2% | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (148.96M) |
| Depreciation & Amortization | 310K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 10.94M |
| Change in Working Capital | 16.78M |
| Accounts Receivables | 0 |
| Inventory | 0 |
| Accounts Payables | 4.69M |
| Other Working Capital | 12.09M |
| Other Non-Cash Items | 714K |
| Operating Cash Flow | (120.21M) |
| Capital Expenditures | (2.09M) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (632.16M) |
| Sales of Investments | 141.65M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (492.6M) |
| Debt Repayment | 100M |
| Common Stock Issued | 498.97M |
| Common Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | (499.19M) |
| Financing Cash Flow | 598.66M |
| Effect of Forex Changes | 0 |
| Net Change in Cash | (14.15M) |
| Free Cash Flow | (122.3M) |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.